By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lipocine Inc. 

675 Arapeen Drive
Suite 202
Salt Lake City  Utah  84108  U.S.A.
Phone: 801-994-7383 Fax:


SEARCH JOBS








Company News
Lipocine (LPCN) Announces Motions Decision By USPTO In Interference Against Clarus Therapeutics 9/21/2017 10:48:28 AM
Lipocine (LPCN) Announces FDA Advisory Committee Meeting For TLANDO 9/20/2017 9:58:51 AM
Lipocine (LPCN) Announces FDA Acknowledgement Of TLANDO (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018 8/14/2017 8:10:35 AM
Lipocine (LPCN) Resubmits NDA For Its Oral Testosterone Product Candidate, LPCN 1021, For Treatment Of Hypogonadism 8/9/2017 10:41:05 AM
Lipocine (LPCN) Announces Financial And Operational Results For The Second Quarter And Six Months Ended June 30, 2017 8/7/2017 12:00:24 PM
Lipocine (LPCN) Announces Submission Of SPA On LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 6/26/2017 9:49:15 AM
Lipocine (LPCN) Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results For LPCN 1021, Oral Testosterone Candidate 6/20/2017 10:43:52 AM
Lipocine (LPCN) Announces Financial And Operational Results For The First Quarter 2017 5/8/2017 10:25:12 AM
Lipocine (LPCN) Completes Enrollment In The LPCN 1021 Fixed Dose Clinical Trials 4/24/2017 10:15:38 AM
Lipocine (LPCN) Announces Financial And Operational Results For The Full Year Of 2016 3/7/2017 11:13:54 AM
123456789
//-->